<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656952</url>
  </required_header>
  <id_info>
    <org_study_id>B7931019</org_study_id>
    <secondary_id>2018-001932-23</secondary_id>
    <nct_id>NCT03656952</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, PLACEBO-AND POSITIVE-CONTROLLED CROSSOVER STUDY TO DETERMINE THE EFFECT OF SINGLE-DOSE PF-06700841 ON QTC INTERVAL IN HEALTHY VOLUNTEERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, 6-sequence, 3-period, subject- and investigator blinded and sponsor-open,
      crossover study in healthy volunteers to evaluate the PF-06700841 effect on QTc interval.
      Each subject randomized will receive placebo, PF-06700841 200 mg and moxifloxacin (open
      label) in one of the 6 sequences. Moxifloxacin is positive control to demonstrate the study
      sensitivity and PF-06700841 effect on QTc will be assessed by concentration-QT analysis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc change from baseline following PF-06700841 treatment</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>QTc change from baseline at geometric mean of maximum concentrations observed after single doses of 200 mg PF-06700841 and maximum concentrations expected at lower doses of 30 and 60 mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTc change from baseline following moxifloxacin treatment</measure>
    <time_frame>0-48 hours post-dose</time_frame>
    <description>QTc change from baseline at 3 hours (Tmax) after a single dose of 400 mg moxifloxacin administration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Seq 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841-&gt; placebo-&gt; moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841-&gt;moxifloxacin-&gt;placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-&gt;PF-06700841-&gt;moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo-&gt;moxifloxacin-&gt;PF-06700841</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin-&gt;PF-06700841-&gt;placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seq 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin-&gt;placebo-&gt;PF-06700841</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <description>a single oral dose of 200 mg PF-06700841</description>
    <arm_group_label>Seq 1</arm_group_label>
    <arm_group_label>Seq 2</arm_group_label>
    <arm_group_label>Seq 3</arm_group_label>
    <arm_group_label>Seq 4</arm_group_label>
    <arm_group_label>Seq 5</arm_group_label>
    <arm_group_label>Seq 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching PF-06700841</description>
    <arm_group_label>Seq 1</arm_group_label>
    <arm_group_label>Seq 2</arm_group_label>
    <arm_group_label>Seq 3</arm_group_label>
    <arm_group_label>Seq 4</arm_group_label>
    <arm_group_label>Seq 5</arm_group_label>
    <arm_group_label>Seq 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>a single oral dose of 400 mg moxifloxacin</description>
    <arm_group_label>Seq 1</arm_group_label>
    <arm_group_label>Seq 2</arm_group_label>
    <arm_group_label>Seq 3</arm_group_label>
    <arm_group_label>Seq 4</arm_group_label>
    <arm_group_label>Seq 5</arm_group_label>
    <arm_group_label>Seq 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential and/or male subjects. Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including BP and pulse rate measurement, 12-lead
             ECG, or clinical laboratory tests.

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb)
             at screening.

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic (including alcoholic liver
             disease, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary
             liver diseases), psychiatric, neurological, or allergic disease (including drug
             allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of
             dosing)

          -  Self-reported history or risk factors for QT prolongation or torsades de pointes (eg,
             organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia,
             congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness,
             family history of sudden death, and family history of long QT syndrome.

          -  Treatment with an investigational drug within 30 days (or as determined by the local
             requirement) or 5 half-lives preceding the first dose of investigational product
             (whichever is longer)

          -  Subjects with known prior participation (ie, randomized and received at least 1 dose
             of investigational product) in a trial involving PF-06700841

          -  History of tuberculosis or active or latent or inadequately treated infection,
             positive QuantiFERON- tuberculosis (TB) Gold test

          -  History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive
             testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody
             (HepBcAb), or hepatitis C antibody (HCVAb)

          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
             within 60 days prior to dosing

          -  Other acute or chronic medical or psychiatric condition including recent (within the
             past year) or active suicidal ideation or behavior or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the subject inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931019&amp;StudyName=A+Phase+1%2C+Randomized%2C+Placebo+And+Positive+Controlled+Crossover+Study+To+Determine+The+Effect+Of+Single+Dose+Pf+06700841+On+Qtc+Interval+In+Healthy+Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7931019&amp;StudyName=A+Phase+1%2C+Randomized%2C+Placebo-and+Positive-controlled+Crossover+Study+To+Determine+The+Effect+Of+Single-dose+Pf-06700841+On+Qtc+Interval+In+Healthy+Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-06700841</keyword>
  <keyword>QT effect</keyword>
  <keyword>concentration-QTc analysis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

